Clinical Trial Applications / CRO

ElucidVivo's unprecedented specificity and ease of use has made it the perfect tool for researchers and pharmaceutical companies to utilize for clinical trial patient selection & longitudinal tracking of plaque regression as a clinical endpoint

Longitudinal Tracking of Plaque Regression
(Clinical Endpoint)

Determine efficacy of drug in clinical trials or during patient care by tracking plaque progression or
regression over time

Longitudinal plaque regression of a patient in response to a therapeutic

Study Example: “Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core.” Choi et al, 2020, Circulation


LRNC key.png

1-Year Follow-Up


Clinical Trial Patient Selection / Exclusion

  • Accurately assess current plaque composition to determine if therapeutic would be appropriate based on parameters of therapeutic indications (e.g., exclude patients with little/no or too severe atherosclerosis, especially for immuno-oncology where plaque may rupture)

  • For disease types beyond cardiovascular (e.g., oncology), exclude patients at high risk of cardiovascular event

CRO Offerings

Elucid offers ElucidVivo quantitative imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigational therapeutic agents to vascular disease. Please contact to learn more.